CP-320626

SKU: orb1697702

Description

CP-320626 is a potent inhibitor of human liver glycogen phosphorylase (GP) and CYP51, exhibiting cholesterol-lowering activity by reducing cholesterol biosynthesis. This dual mechanism supports its application in type 2 diabetes research, with studies demonstrating efficacy in relevant in vitro and in vivo metabolic models.

Research Area

Infectious Disease & Virology, Metabolism Research

Key Properties

• CAS Number: 186430-23-9
• MW: 443.9
• Purity: 98.06% (May vary between batches)
• Formula: C₂₃H₂₃ClFN₃O₃
• SMILES: C(N[C@H](C(=O)N1CCC(O)CC1)CC2=CC=C(F)C=C2)(=O)C=3NC=4C(C3)=CC(Cl)=CC4
• Target: Phosphorylase,Others,Parasite

Bioactivity

• Target IC50:
  GP:205 nM
• In Vivo:
  In ob/ob mice, acute treatment with CP-320626 resulted in reduced liver cholesterol production, accompanied by lanosterol accumulation, further suggesting that CYP51 inhibition is the mechanism of cholesterol reduction in these animals.
  Read more...
• In Vitro:
  Treatment of MIA PaCa-2 cancer cells with CP-320626 (25, 50 and 100 μM) showed significant changes in the dynamic expression of total protein and phosphoprotein. CP-320626 inhibits cholesterol production by directly inhibiting CYP51. CP-320626 (50-100 μM) regulates glucose homeostasis by inhibiting glycogen phosphorylase (GP) and thereby affecting glucose production.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CP 320626, CP-320626, CP320626

Compound Identifiers

PubChem CID

444746